Fatty Liver Disease Linked to Metabolism Problems and Heart Failure with Normal Pumping Function

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease globally.

• MASLD and heart failure with preserved ejection fraction (HFpEF) share common metabolic dysfunction as a foundational factor.
• There is a significant overlap in the underlying mechanisms of MASLD and HFpEF, including metabolic, inflammatory, and fibrotic pathways.
• The degree of hepatic fibrosis in MASLD is correlated with the prognosis and severity of HFpEF.
• Shared risk factors contribute to a strong bidirectional association between MASLD and cardiovascular diseases, especially HFpEF.
• Emerging treatments targeting both MASLD and HFpEF highlight the need for integrated care approaches.

Simplified